蒲地蓝消炎口服液联合支气管扩张药物治疗稳定期中重度COPD的临床观察

发布时间：2018-03-12 19:07

本文选题：慢性阻塞性肺疾病　切入点：蒲地蓝消炎口服液　出处：《中国药房》2015年26期 　论文类型：期刊论文

【摘要】：目的:观察蒲地蓝消炎口服液联合支气管扩张药物治疗稳定期中重度慢性阻塞性肺疾病(COPD)患者的临床疗效及安全性。方法:选取104例稳定期中重度COPD患者,按照入院时间随机分为治疗组(53例)和对照组(49例)。对照组患者给予布地奈德福莫特罗粉吸入剂与噻托溴铵干粉吸入剂进行治疗,治疗组患者在对照组基础上加用蒲地蓝消炎口服液,10 ml/次,3次/d。疗程均为12周。观察并比较两组患者肺功能指标、急性加重次数、呼吸困难评分(m MRC)、COPD评估测试(CAT)评分、COPD临床调查问卷(CCQ)评分等指标。结果:治疗12周后,治疗组患者深吸气量与治疗前及对照组比较均有明显改善,差异有统计学意义(P0.05),但其第1秒用力呼气容积、第1秒用力呼气容积占用力肺活量比值与治疗前及对照组比较,差异无统计学意义(P0.05);两组患者急性加重次数比较,差异无统计学意义(P0.05);治疗组患者m MRC、CAT评分和CCQ总分与治疗前及对照组比较均有明显降低,差异有统计学意义(P0.05)。两组患者均未见明显不良反应发生。结论:蒲地蓝消炎口服液联合支气管扩张药物吸入治疗稳定期中重度COPD的临床疗效优于单用干粉制剂吸入治疗,可明显改善患者肺功能,增加患者运动耐量,提高患者生存质量。
[Abstract]:Objective: to observe the clinical efficacy and safety of Pudilanxiaoyan oral liquid combined with bronchiectasis in the treatment of moderate and severe chronic obstructive pulmonary disease (COPD) in stable period. The patients in the control group were treated with budesonide formoterol powder inhalation and tiotropium bromide dry powder inhalation. The patients in the treatment group were treated with 10 ml/ oral solution of Pudilan Xiaoyan oral liquid for 3 times / d on the basis of the control group. The course of treatment was 12 weeks. The pulmonary function index and acute exacerbation times were observed and compared between the two groups. Results: after 12 weeks of treatment, the inspiratory volume of the patients in the treatment group was significantly improved compared with that before treatment and the control group. The difference was statistically significant (P 0.05), but the ratio of forced expiratory volume at 1 seconds and forced expiratory volume at 1 seconds was not significantly different from that before treatment and control group. The cat score and total CCQ score of the patients in the treatment group were significantly lower than those before the treatment and those in the control group. The difference was statistically significant (P 0.05). There was no significant adverse reaction between the two groups. Conclusion: the clinical efficacy of Polan Xiaoyan Oral liquid combined with bronchiectasis in the treatment of moderate and severe COPD in stable period is better than that in dry powder preparation alone. It can obviously improve the pulmonary function, increase the patient's exercise tolerance and improve the patient's quality of life.
【作者单位】：山东大学齐鲁医院呼吸科;
【基金】：国家自然科学基金资助项目(No.81270072)
【分类号】：R563.9

【参考文献】